Small molecule biotechnology company Iambic Therapeutics (IAM.US) sets IPO price at $15-17 per share, plans to raise $150 millions

智通财经2026/10/09 07:06

Show original

According to Jinse Finance, it has been reported that Iambic Therapeutics (IAM.US), a biotechnology company developing small-molecule anti-cancer therapies based on its self-developed artificial intelligence (AI) platform and currently in Phase I clinical trials, announced its IPO terms on Thursday. The San Diego, California-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have already expressed their intention to purchase $60 million worth of shares in this offering, accounting for 40% of the deal. At the midpoint of the proposed price range, Iambic Therapeutics would have a fully diluted market value of $809 million.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.